<DOC>
	<DOCNO>NCT00547547</DOCNO>
	<brief_summary>RATIONALE : Brassica juncea contains high amount selenium may slow growth cancer cell . Drugs use chemotherapy , irinotecan capecitabine , work different way stop growth cancer cell , either kill cell stop divide . Giving high-selenium Brassica juncea together combination chemotherapy may kill cancer cell . PURPOSE : This phase I trial study side effect best dose high-selenium Brassica juncea capecitabine give together irinotecan treat patient advanced cancer .</brief_summary>
	<brief_title>High-Selenium Brassica Juncea , Irinotecan , Capecitabine Treating Patients With Advanced Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum tolerate dose high-selenium Brassica juncea ( BJ-Se ) capecitabine administer combination irinotecan hydrochloride patient advanced malignancy . - To determine effect BJ-Se pharmacokinetics irinotecan hydrochloride capecitabine . Secondary - To determine effect BJ-Se serum selenium protein profile . - To correlate response tolerance regimen expression key enzyme involve target metabolism component treatment , include thymidylate synthase dihydropyrimidine dehydrogenase . - To evaluate change potential selenium related parameter . OUTLINE : This multicenter , dose-escalation study high-selenium Brassica juncea ( BJ-Se ) capecitabine . The dose capecitabine escalate first , follow dose escalation BJ-Se . Patients receive oral BJ-Se day -7 21 course 1 day 1-21 course . Patients also receive irinotecan IV day 1 8 oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day absence unacceptable toxicity disease progression . After maximum tolerate dose ( MTD ) capecitabine BJ-Se determine , additional patient accrue receive treatment MTD . Blood collect patient course 1 pharmacokinetic study .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Selenium</mesh_term>
	<criteria>Patients advance , biopsyproven cancer standard curative therapy Karnofsky Performance status &gt; = 60 Prior therapy complete least 3 week protocol treatment initiation recovery sideeffects Prior capecitabine and/or irinotecan allow subject progress treatment within 6 month treatment medication either alone combination Prior radiation therapy allow &lt; 30 % marrow treat Alanine aminotransferase ( ALT ) alkaline phosphatase 3x upper limit normal Serum bilirubin within normal limit Absolute neutrophil count &gt; = 15000/ul Platelet count &gt; = 100,000/ul Hemoglobin &gt; = 10 gm/dl transfusion allow achieve Serum creatinine within 1.5 x upper limit normal Ability understand sign IRB approve informed consent Ability use appropriate contraception evidence pregnancy female patient reproductive potential No significant medical psychiatric condition would make treatment unsafe No active brain metastasis ( patient treat brain metastasis stable steroid eligible ) Nursing woman Patients must able comply protocol related study followup Patients UGT1a1 7/7 positive exclude dose escalation portion trial , may participate cohort patient treat MTD</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>